HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer


Fig. 2

Cytotoxic activity of T-AuNPs towards gastric cancer cell lines

(A) Expression levels of HER2, EGFR and PTEN in MKN7, NCI-N87, MKN74 and NHLF cells were examined on western blot analysis. (B) The viability of NCI-N87 cells was assessed using an XTT assay at 72 hours after treatment with several doses of C-AuNPs, Tmab, or T-AuNPs. Dose–response curves are shown. Doses are described based on a dose (μl) of each agent added in a 96-well plate in this experiment. The intersection of each curve with the horizontal dashed line shows the IC50 dose of each treatment. (C) The viability of the four cell lines, MKN7, NCI-N87, MKN74 and NHLF, was assessed using an XTT assay at 72 hours after PBS, C-AuNPs (4.6 × 109 particles/ml), Tmab (1.3 μg/ml), T-AuNPs (4.6 × 109 particles/ml) or Tmab+C-AuNPs treatment. Note that although MKN7 and NCI-N87 are both HER2-positve, MKN7 is Tmab-resistant. **, P < 0.01. ***, P < 0.001.

Source link


Please enter your comment!
Please enter your name here